临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 220991-20-8

Lumiracoxib

中文名称:罗美昔布
CAS号:220991-20-8
分子式: C15H13ClFNO2 分子量: 293.72
产品形式: free base
研发状态: Completed
研发用途: Healthy Volunteers
研究机构: Novartis
研发日期: May-06
研发阶段: Phase 4
Lumiracoxib (COX-189) is a novel, selective COX-2 inhibitor with Ki of 0.06 μM. It also inhibits COX1 with Ki of 3 μM.

CAS: 22071-15-4

Ketoprofen

中文名称:酮洛芬
CAS号:22071-15-4
分子式: C16H14O3 分子量: 254.28
产品形式: free base
研发状态: Completed
研发用途: Healthy
研究机构: Aziende Chimiche Riunite Angelini Francesco S.p.A; Cross Research S.A.
研发日期: July 23 2018
研发阶段: Phase 1
Ketoprofen (RP-19583) is a dual COX1/2 inhibitor, used as a nonsteroidal anti-inflammatory drug to treat arthritis-related inflammatory pains.

CAS: 220620-09-7

Tigecycline (GAR-936)

中文名称:替加环素
CAS号:220620-09-7
分子式: C29H39N5O8 分子量: 585.65
产品形式: free base
研发状态: Recruiting
研发用途: Carbapenem-resistant Enterobacteriaceae
研究机构: Phramongkutklao College of Medicine and Hospital; Silpakorn University
研发日期: September 17 2023
研发阶段: Not Applicable
Tigecycline (Tygacil, GAR-936, WAY-GAR-936, TBG-MINO) is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation. Tigecycline induces autophagy by downregulating the PI3K-AKT-mTOR pathway.

CAS: 22033-87-0

Olesoxime (TRO 19622)

中文名称:奥利索西
CAS号:22033-87-0
分子式: C27H45NO 分子量: 399.65
产品形式: Free Base
研发状态: Completed
研发用途: Muscular Atrophy Spinal
研究机构: Hoffmann-La Roche
研发日期: January 20 2016
研发阶段: Phase 2
Olesoxime (TRO19622) is a novel, orally active and CNS-penetrant mitochondrial-targeted neuroprotective compound.

CAS: 220127-57-1

Imatinib (STI571) Mesylate

中文名称:甲磺酸伊马替尼
CAS号:220127-57-1
分子式: C29H31N7O.CH4SO3 分子量: 589.71
产品形式: Mesylate
研发状态: Recruiting
研发用途: CML
研究机构: Inhibikase Therapeutics Inc.
研发日期: December 16 2022
研发阶段: Phase 1
Imatinib (STI571, CGP057148B, Gleevec) Mesylate is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib Mesylate (STI571) induces autophagy.

CAS: 219989-84-1

Ixabepilone (BMS-247550)

中文名称:伊沙匹隆
CAS号:219989-84-1
分子式: C27H42N2O5S 分子量: 506.70
产品形式: Free base
研发状态: Completed
研发用途: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
研究机构: Yale University; R-Pharm-US LLC
研发日期: April 3 2017
研发阶段: Phase 2
Ixabepilone (Azaepothilone B, BMS-247550, Ixempra, Aza-epothilone B) is an orally bioavailable microtubule inhibitor. It binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis.